Press

2026 Fierce AI Innovation Awards: Clinical Trial Design, Unlearn

Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs

Unlearn to Support SOLA Biosciences' Clinical Study Using AI-Generated Digital Twins

Unlearn Advances Huntington's Disease AI Modeling Through Access to CHDI Foundation Data

Unlearn to Apply AI-Generated Digital Twins to the VectorY Therapeutics PIONEER-ALS Study

Unlearn Introduces TrialPioneer, an AI-powered Workspace to Strengthen Upstream Trial Planning

Digital Twins: The Sci-Fi Innovation Behind New Personalized Disease Treatments

Dr. Robert Lenz Joins Unlearn as Strategic Advisor

Digital Twins Grow Up But Adoption Hurdles Remain

Digital twins for the personal touch

Clean and harmonised CRM data vital for AI model training

What the Future Holds for Clinical Trials as AI and Digital Twins Become More Embedded

Understanding FDA and EMA Guidance on AI and Digital Twin Applications in Trials

Unlearn Appoints Its First Vice President of Product

The AI model that is changing clinical trial design

AI-Powered Digital Twins Give Clinical Trials a 75-Year Upgrade

The Future Of Drug Trials Might Be Virtual AI Patients

Unlearn Appoints Krates Ng as Chief Technology Officer

Unlearn and remynd Partner on Alzheimer’s Study to Strengthen Confidence in Early Clinical Signals Using Digital Twins

Unlearn and Trace Neuroscience Partner to Optimize ALS Clinical Trial